Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics

Zentalis Pharmaceuticals Inc. (ZNTL): $24.75

2.42 (+10.84%)

POWR Rating

Component Grades













Add ZNTL to Watchlist
Sign Up

Industry: Biotech



in industry

ZNTL Stock Price Chart Interactive Chart >

Price chart for ZNTL

ZNTL Price/Volume Stats

Current price $24.75 52-week high $87.19
Prev. close $22.33 52-week low $17.33
Day low $21.92 Volume 933,400
Day high $25.32 Avg. volume 619,457
50-day MA $31.36 Dividend yield N/A
200-day MA $57.80 Market Cap 1.15B

Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

ZNTL Latest News Stream

Event/Time News Detail
Loading, please wait...

ZNTL Latest Social Stream

Loading social stream, please wait...

View Full ZNTL Social Stream

Latest ZNTL News From Around the Web

Below are the latest news stories about Zentalis Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor, ZN-c3, for the treatment of uterine serous carcinoma (USC) Initiated two additional trials with ZN-c3, including a potentially registrational biomarker-driven Phase 2 trial and a Phase 1/2 trial in combination with GSK’s PARP inhibitor, niraparib, in ovarian cancer Announced the addition of a preclinical BCL-xL heterobifunctional degrader candidate to its pipeline Ended year with $339.9 million in ca

Yahoo | February 24, 2022

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

NEW YORK and SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences. Presentation Details: Event: Guggenheim Oncology ConferenceDate

Yahoo | February 3, 2022

Leerink Partners Maintains a Buy Rating on Zentalis Pharmaceuticals (ZNTL)

Leerink Partners analyst Andrew Berens maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday. The company's shares closed last Wednesday at $72.81. According to TipRanks.com, Berens has 0 stars on 0-5 stars ranking scale with an average return of -3.8% and a 44.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Zentalis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $104.33. See the top stocks recommended by analysts >> The company has a one-year high of $87.19 and a one-year low of $34.48.

Catie Powers on TipRanks | January 6, 2022

Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $792,400 of Shares

COO of Zentalis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Kevin D. Bunker (insider trades) sold 10,000 shares of ZNTL on 12/20/2021 at an average price of $79.24 a share.

Yahoo | December 22, 2021

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | December 21, 2021

Read More 'ZNTL' Stories Here

ZNTL Price Returns

1-mo -4.22%
3-mo -51.77%
6-mo -68.11%
1-year -55.68%
3-year N/A
5-year N/A
YTD -70.56%
2021 61.84%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5634 seconds.